COSCIENS Biopharma Inc. Welcomes New Interim CEO
COSCIENS Biopharma Inc. (TSX: CSCI) is excited to announce a pivotal leadership change. The life science company, known for its innovative natural ingredients and pharmaceutical solutions, has appointed Peter H. Puccetti, CFA, as the Interim Chief Executive Officer. This transition comes as the Company aims to refine its cost structure and realign its operational focus on key strategic priorities.
Leadership Transition and Strategic Direction
Peter Puccetti, who already plays a crucial role as Chairman of the Board, will now take on the additional responsibilities of Interim CEO. His impending leadership was highlighted by Robert Seager, the Chair of the Human Resources, Nominating and Governance Committee. Seager emphasized that now is an optimal moment for this leadership transition as the Company sets its sights on a streamlined organizational structure.
The Board is confident that Peter, with his extensive background in driving strategic initiatives and enhancing company performance, will lead COSCIENS through this period of transformation successfully. Peter expressed his commitment to not only enhance operational efficiencies but also to foster growth and shareholder value during his tenure. He acknowledged Anna Biehn's contributions as the outgoing CEO, thanking her for her dedication and leadership.
About COSCIENS Biopharma Inc.
COSCIENS is recognized in the life science field for its diverse portfolio centered on the development of natural, plant-based active ingredients. The Company is heavily invested in commercializing pharmaceutical and diagnostic products, showcasing its commitment to innovation. One of the flagship products, Macimorelin (Macrilen; Ghryvelin), marks a significant milestone as the first oral test approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for diagnosing adult growth hormone deficiency (AGHD).
Expertise in Natural Active Ingredients
The Company utilizes its proprietary manufacturing and extraction technologies to develop unique active ingredients, such as Avenanthramides and Beta Glucan. These components are utilized globally, particularly in top skincare brands, demonstrating COSCIENS' influence on the beauty and health market.
Market Activity and Stock Information
Trading under the symbol CSCI on the Toronto Stock Exchange, COSCIENS has also made its common shares available in the U.S. as CSCIF by FINRA's Department of Market Operations for OTC trading since early September 2025. This dual listing exemplifies COSCIENS' strategic positioning for growth in North America, one of the most lucrative markets for pharmaceutical developments.
Future Outlook of COSCIENS
With Peter Puccetti stepping into the dual roles of Chairman and Interim CEO, COSCIENS is poised for an exciting phase ahead. The Company's focus on enhancing operational performance and its commitment to delivering value will be paramount as it navigates the complexities of the market.
Frequently Asked Questions
Who is the new Interim CEO of COSCIENS Biopharma?
Peter H. Puccetti has been named Interim CEO of COSCIENS Biopharma Inc.
What are the primary focuses of COSCIENS Biopharma?
The Company concentrates on developing natural ingredients and pharmaceutical solutions, particularly in the growth hormone deficiency space.
What notable product does COSCIENS Biopharma offer?
COSCIENS' lead product is Macimorelin, the first FDA and EMA approved oral test for adult growth hormone deficiency.
Where are COSCIENS Biopharma’s shares listed?
The Company's shares are listed on the Toronto Stock Exchange under the ticker symbol CSCI.
How has the leadership transition been communicated?
The transition has been communicated through official press releases, emphasizing strategic realignment and a focus on shareholder value.
